We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi beats Q3 earnings and sales estimates, with earnings rising 19.6% and net sales growing 14.3% at CER.
Dupixent sales surge 34.8% year-over-year, while rare disease & established medicines deliver mixed results.
Sanofi raises its 2026 sales growth outlook to low teens at CER and expects business EPS to rise by mid-teens.
Sanofi (SNY - Free Report) reported third-quarter 2026 adjusted earnings of $2.04 per American depositary share, which comprehensively beat the Zacks Consensus Estimate of $1.63 per share. Earnings of €3.55 per share rose 22% on a reported basis and 19.6% on a constant currency rate (“CER”) basis.
Revenues of $16.62 billion surpassed the Zacks Consensus Estimate of $15.23 billion. Net sales of €14.44 billion rose 16.2% on a reported basis and 14.3% at CER, driven by Dupixent and new and recently acquired medicines.
All growth rates mentioned below are on a year-on-year basis and at CER.
SNY's Dupixent Sales Maintain Strong Momentum
In Immunology, blockbuster drug Dupixent sales climbed 34.8% to €5.69 billion. Growth reflected strong demand across approved indications and increased use of advanced treatments. U.S. sales jumped 40.2% to €4.38 billion, aided by favorable gross-to-net price adjustments. Sales advanced 16.1% in Europe to €588 million and 22.6% in the Rest of the World to €723 million, supported by Japan, Canada, Brazil and China.
Sanofi markets Dupixent in partnership with Regeneron (REGN - Free Report) . While sales are recorded by Sanofi, Regeneron records its share of profits/losses in connection with global sales of Dupixent.
Sanofi's Rare Disease Portfolio Shows Strength
Among rare disease medicines, Altuviiio sales increased 37.8% to €408 million, supported by patients switching from older factor therapies. The United States accounted for approximately 85% of quarterly sales.
Ayvakit sales climbed 46% to €203 million, reflecting continued growth in patient numbers and treatment duration. The drug was added through the Blueprint Medicines acquisition.
Nexviazyme/Nexviadyme sales rose 4% to €211 million, while Myozyme/Lumizyme revenues declined 15.6% to €105 million as patients switched to the newer treatment. The combined Pompe disease franchise generated €316 million, down 3.4%.
Fabrazyme sales increased 6.2% to €260 million. Alprolix rose 13.4% to €172 million, while Cablivi and Xenpozyme advanced 6.1% and 8.8%, respectively. Newer drugs Wayrilz and Qfitlia contributed €19 million and €8 million, respectively, compared with €17 million and €7 million in the previous quarters.
SNY's Established Medicines Deliver Mixed Results
Among other major medicines, Lantus sales rose 18.5% to €530 million, driven by favorable U.S. pricing adjustments, market-share gains and temporary demand resulting from competitor supply disruptions.
Toujeo sales jumped 31.2% to €430 million, supported by U.S. market-share gains and favorable pricing adjustments. Rezurock advanced 43% to €165 million, while Praluent increased 20.5% to €156 million.
Oncology drug Sarclisa generated €196 million, up 25.8%, benefiting from increased use in earlier treatment lines and the ongoing launch of its subcutaneous formulation.
However, legacy medicines remained under pressure. Plavix sales declined 10.8% to €206 million, while Lovenox dropped 12.8% to €174 million amid continued biosimilar competition.
SNY's Vaccine Sales Decline Again in Q3
Vaccine sales decreased 6.6% to €3.19 billion, primarily due to the timing of seasonal influenza vaccine deliveries and lower U.S. Beyfortus sales.
Influenza and COVID-19 vaccine revenues fell 18.8% to €1.26 billion.
Revenues of Sanofi and partner AstraZeneca’s (AZN - Free Report) respiratory syncytial virus or RSV antibody, Beyfortus, declined 15.4% to €631 million, reflecting a lower U.S. order from the Centers for Disease Control and Prevention.
Meanwhile, polio, pertussis and Hib vaccines, including Heplisav-B, recorded 24.9% sales growth to €823 million, benefiting from the newly acquired vaccine. Meningitis, travel and endemic vaccine sales increased 4.2% to €476 million.
Sanofi Raises Its 2026 Outlook
Sanofi now expects sales to grow by a low-teens percentage at CER, compared with its previous projection of approximately 10% growth at CER.
Business earnings per share are now expected to increase by a mid-teens percentage, which was previously expected to increase slightly faster than sales at CER.
Shares of Sanofi were up more than 3% in pre-market trading on Friday owing to the better-than-expected earnings results as well as the raised 2026 outlook.
Year to date, shares of Sanofi have declined 7.4% against the industry’s increase of 20.3%.
Image Source: Zacks Investment Research
Our Take on SNY’s Q3 Results
Sanofi delivered a strong quarter, beating earnings and revenue estimates as Dupixent crossed the €5-billion quarterly sales mark for the second time in a row.
Dupixent remained the key growth driver while strong demand for Altuviiio, Ayvakit and Rezurock also supported top-line growth. However, vaccine sales declined again in the quarter.
Sanofi also raised its earnings and sales growth expectations for the year based on a strong performance in the first nine months of 2026. Its recently expanded collaboration with Regeneron also strengthens its longer-term immunology pipeline.
View the Zacks #1 Rank List
Image: Bigstock
Sanofi Q3 Earnings & Sales Beat, 2026 View Up, Shares Rise
Key Takeaways
Sanofi (SNY - Free Report) reported third-quarter 2026 adjusted earnings of $2.04 per American depositary share, which comprehensively beat the Zacks Consensus Estimate of $1.63 per share. Earnings of €3.55 per share rose 22% on a reported basis and 19.6% on a constant currency rate (“CER”) basis.
Revenues of $16.62 billion surpassed the Zacks Consensus Estimate of $15.23 billion. Net sales of €14.44 billion rose 16.2% on a reported basis and 14.3% at CER, driven by Dupixent and new and recently acquired medicines.
All growth rates mentioned below are on a year-on-year basis and at CER.
SNY's Dupixent Sales Maintain Strong Momentum
In Immunology, blockbuster drug Dupixent sales climbed 34.8% to €5.69 billion. Growth reflected strong demand across approved indications and increased use of advanced treatments. U.S. sales jumped 40.2% to €4.38 billion, aided by favorable gross-to-net price adjustments. Sales advanced 16.1% in Europe to €588 million and 22.6% in the Rest of the World to €723 million, supported by Japan, Canada, Brazil and China.
Sanofi markets Dupixent in partnership with Regeneron (REGN - Free Report) . While sales are recorded by Sanofi, Regeneron records its share of profits/losses in connection with global sales of Dupixent.
Sanofi's Rare Disease Portfolio Shows Strength
Among rare disease medicines, Altuviiio sales increased 37.8% to €408 million, supported by patients switching from older factor therapies. The United States accounted for approximately 85% of quarterly sales.
Ayvakit sales climbed 46% to €203 million, reflecting continued growth in patient numbers and treatment duration. The drug was added through the Blueprint Medicines acquisition.
Nexviazyme/Nexviadyme sales rose 4% to €211 million, while Myozyme/Lumizyme revenues declined 15.6% to €105 million as patients switched to the newer treatment. The combined Pompe disease franchise generated €316 million, down 3.4%.
Fabrazyme sales increased 6.2% to €260 million. Alprolix rose 13.4% to €172 million, while Cablivi and Xenpozyme advanced 6.1% and 8.8%, respectively. Newer drugs Wayrilz and Qfitlia contributed €19 million and €8 million, respectively, compared with €17 million and €7 million in the previous quarters.
SNY's Established Medicines Deliver Mixed Results
Among other major medicines, Lantus sales rose 18.5% to €530 million, driven by favorable U.S. pricing adjustments, market-share gains and temporary demand resulting from competitor supply disruptions.
Toujeo sales jumped 31.2% to €430 million, supported by U.S. market-share gains and favorable pricing adjustments. Rezurock advanced 43% to €165 million, while Praluent increased 20.5% to €156 million.
Oncology drug Sarclisa generated €196 million, up 25.8%, benefiting from increased use in earlier treatment lines and the ongoing launch of its subcutaneous formulation.
However, legacy medicines remained under pressure. Plavix sales declined 10.8% to €206 million, while Lovenox dropped 12.8% to €174 million amid continued biosimilar competition.
SNY's Vaccine Sales Decline Again in Q3
Vaccine sales decreased 6.6% to €3.19 billion, primarily due to the timing of seasonal influenza vaccine deliveries and lower U.S. Beyfortus sales.
Influenza and COVID-19 vaccine revenues fell 18.8% to €1.26 billion.
Revenues of Sanofi and partner AstraZeneca’s (AZN - Free Report) respiratory syncytial virus or RSV antibody, Beyfortus, declined 15.4% to €631 million, reflecting a lower U.S. order from the Centers for Disease Control and Prevention.
Meanwhile, polio, pertussis and Hib vaccines, including Heplisav-B, recorded 24.9% sales growth to €823 million, benefiting from the newly acquired vaccine. Meningitis, travel and endemic vaccine sales increased 4.2% to €476 million.
Sanofi Raises Its 2026 Outlook
Sanofi now expects sales to grow by a low-teens percentage at CER, compared with its previous projection of approximately 10% growth at CER.
Business earnings per share are now expected to increase by a mid-teens percentage, which was previously expected to increase slightly faster than sales at CER.
Shares of Sanofi were up more than 3% in pre-market trading on Friday owing to the better-than-expected earnings results as well as the raised 2026 outlook.
Year to date, shares of Sanofi have declined 7.4% against the industry’s increase of 20.3%.
Image Source: Zacks Investment Research
Our Take on SNY’s Q3 Results
Sanofi delivered a strong quarter, beating earnings and revenue estimates as Dupixent crossed the €5-billion quarterly sales mark for the second time in a row.
Dupixent remained the key growth driver while strong demand for Altuviiio, Ayvakit and Rezurock also supported top-line growth. However, vaccine sales declined again in the quarter.
Sanofi also raised its earnings and sales growth expectations for the year based on a strong performance in the first nine months of 2026. Its recently expanded collaboration with Regeneron also strengthens its longer-term immunology pipeline.
Sanofi Price, Consensus and EPS Surprise
Sanofi price-consensus-eps-surprise-chart | Sanofi Quote
SNY’s Zacks Rank
Sanofi currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.